2-CHLORODEOXYADENOSINE (2CDA) FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

2-氯脱氧腺苷 (2CDA) 治疗慢性进行性多发性硬化症

• 批准号: 6279272
• 负责人: JACK C SIPE
• 金额: $ 2.73万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279272
• 关键词: artificial immunosuppression; chlorodeoxyadenosine; clinical research; drug screening /evaluation; human subject; human therapy evaluation; immunosuppressive; multiple sclerosis; nervous system disorder chemotherapy; placebos

Multiple sclerosis (MS) is a progressive neurologic disorder that is likely to have an autoimmune basis. We have been testing the safety and efficacy of cladribine (2-CdA) as a treatment for MS. Other current treatments are unsatisfactory, with Beta Interferon and Copaxone having a partial effect on relapses in MS. We have completed treatment trials in chronic progressive MS and have shown that cladribine, an immuno- suppressive agent, retards the progression of the disease for two years or longer. A double-blind, placebo-controlled clinical trial of cladribine in relapsing remitting MS (subproject #288) has just been completed. The results indicate marked suppression of MRI-enhancing brain lesions in the cladribine treated group and significant reduction in both severity and frequency of clinical relapses. There was no significant toxicity or side effects of subcutaneously administered cladribine at the doses used in this study.

多发性硬化症（MS）是一种进行性神经系统疾病， 很可能是自身免疫性疾病我们一直在测试安全性 克拉屈滨（2-CdA）作为MS治疗有效性 治疗是不令人满意的，β干扰素和克帕松具有 对多发性硬化症的复发有部分效果。我们已经完成了治疗试验 在慢性进行性MS中，克拉屈滨，一种免疫调节剂， 抑制剂，延缓疾病的进展两年 或者更长。 一项双盲、安慰剂对照临床试验， 克拉屈滨治疗复发缓解型MS（子项目#288）刚刚被 完成 结果表明MRI增强的显著抑制 克拉屈滨治疗组的脑病变明显减少 临床复发的严重程度和频率。没有 皮下给药的显著毒性或副作用 克拉屈滨在本研究中使用的剂量。